valganciclovir hydrochloride 50 mg/mL (Valganciclovir Hydrochloride FOR SOLUTION) 50 mg/mL

Valganciclovir is a prodrug of ganciclovir. After oral absorption, it is converted to ganciclovir, which is phosphorylated by viral kinases and inhibits viral DNA polymerase. This action prevents the synthesis of viral DNA, thereby stopping the replication of the cytomegalovirus (CMV).

The dosage of valganciclovir hydrochloride 50 mg/mL is determined by a healthcare provider based on the patient's condition, age, and renal function. It is important to follow the prescribed dosage and administration instructions provided by the healthcare professional.

Valganciclovir should be avoided during pregnancy due to potential fetal toxicity. It is also not recommended during breastfeeding as it may pass into breast milk. Pregnant or breastfeeding women should consult their healthcare provider for alternative treatment options.

To order valganciclovir hydrochloride 50 mg/mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the necessary import paperwork.

Valganciclovir is specifically indicated for the treatment and prevention of CMV infections. It is more convenient to administer than ganciclovir, as it can be taken orally. The choice between valganciclovir and other antiviral drugs depends on the specific condition being treated and the patient's medical history.

Valganciclovir hydrochloride 50 mg/mL should be stored below 25°C, in the original pack, and protected from moisture. It is important to follow the storage instructions provided to maintain the medication's effectiveness and safety.

Valganciclovir hydrochloride 50 mg/mL is administered orally, with the solution prepared by the pharmacist prior to dispensing. It should be taken with food as directed by the healthcare provider. The dosage and duration of treatment will be determined by the healthcare professional based on the patient's condition.

The most serious risks associated with valganciclovir include severe leukopenia, neutropenia, anemia, thrombocytopenia, bone marrow suppression, and aplastic anemia. Regular blood tests are required to monitor for these potential side effects. Patients should also be monitored for signs of renal toxicity and impairment of fertility.

Valganciclovir hydrochloride 50 mg/mL should not be used by individuals with a known hypersensitivity to valganciclovir, ganciclovir, or any of the excipients in the formulation. It should also be avoided in patients with severe renal impairment, severe bone marrow suppression, or during pregnancy unless the potential benefits outweigh the risks.